Atai Life Sciences (NASDAQ: ATAI) has initiated a Phase 1b trial of VLS-01, an oral transmucosal film of N,N-dimethyltryptamine (DMT). The trial, involving 16 healthy participants, will assess safety, tolerability, and pharmacokinetics compared to intravenous administration. Atai anticipates results in the second half of the year. Florian Brand, Atai’s CEO, expressed enthusiasm for the trial’s swift commencement.
Read the full story here
Written by: Debra Borchardt
Published on March 5, 2024 at 03:07AM
Source: Green Market Report (opens in new tab)